Acticor Biotech posted a technical rebound on the Paris Bourse on Friday, after plummeting the previous day due to the failure of its Phase 2/3 trial in stroke treatment.As mid-day approached, the.
Acticor Biotech announced on Thursday that a Phase 2/3 clinical trial had failed to meet its endpoints in the treatment of stroke, resulting in a suspension of its share price.The biopharmaceutical.
Analysis of the primary and secondary endpoints of the phase 2/3 ACTISAVE study showed no improved efficacy with glenzocimab
Key results from this study will be presented at ESOC on May 15,.
ACTICOR BIOTECH: Disclosure of the Total Number of Voting Rights and Shares as of March 31, 2024 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
The University of Birmingham and Acticor Biotech Announce the First Patient Treated in LIBERATE, First Clinical Trial Evaluating Glenzocimab for Heart Attacks finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.